This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2) limiting the scope and number of patents asserted in litigation against proposed biosimilar entrants. 3) policing anticompetitive settlements between competing drug manufacturers. 4) prohibiting ‘product hopping’ and interference with generic and biosimilar substitutions. 5) monitoring access to biosimilars.
His practice supports clients throughout the life sciences from biotech startups and multinational pharmaceuticalcompanies to CROs and academic researchers to patient advocacy organizations.
With growing awareness of the environmental impact of pharmaceuticalmanufacturing—such as pollution from toxic discharges—companies must adopt more sustainable practices. One of the primary challenges the industry faces is the inherent resource intensity of pharmaceuticalmanufacturing.
The speakers shared their views on the topic: Dr. Jagadeesh Babu Rangisetty- “COVID has taught us so many things and the pharmaceuticalcompany has gone through a lot of challenges and at the same time opportunities. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content